{"id":851975,"date":"2025-05-16T13:22:49","date_gmt":"2025-05-16T17:22:49","guid":{"rendered":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-zenas-biopharma-inc-should-contact-levi-korsinsky-before-june-16-2025-to-discuss-your-rights-zbio-2\/"},"modified":"2025-05-16T13:22:49","modified_gmt":"2025-05-16T17:22:49","slug":"shareholders-of-zenas-biopharma-inc-should-contact-levi-korsinsky-before-june-16-2025-to-discuss-your-rights-zbio-2","status":"publish","type":"post","link":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-zenas-biopharma-inc-should-contact-levi-korsinsky-before-june-16-2025-to-discuss-your-rights-zbio-2\/","title":{"rendered":"Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights \u2013 ZBIO"},"content":{"rendered":"
\n

NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc.<\/strong> (“Zenas BioPharma, Inc.” or the “Company”) (NASDAQ: ZBIO) of a class action securities lawsuit.<\/p>\n

\n CLASS DEFINITION: <\/strong>The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and\/or traceable to the registration statement and related prospectus issued in connection with Zenas BioPharma\u2019s September 2024 initial public offering. Follow the link below to get more information and be contacted by a member of our team:<\/p>\n

\n https:\/\/zlk.com\/pslra-1\/zenas-biopharma-inc-lawsuit-submission-form?prid=148677&wire=3<\/a>\n <\/p>\n

\n ZBIO<\/strong> investors may also contact Joseph E. Levi, Esq. via email at\u00a0jlevi@levikorsinsky.com<\/a>\u00a0or by telephone at (212) 363-7500.<\/p>\n

\n CASE DETAILS: <\/strong>The filed complaint alleges that defendants made false statements and\/or concealed that: (1) Zenas BioPharma materially overstated the amount of time that it would be able to fund its operations using existing cash and expected net proceeds from the IPO; and (2) as a result, defendants\u2019 public statements were materially false and misleading at all relevant times and negligently prepared.<\/p>\n

\n WHAT’S NEXT? <\/strong>If you suffered a loss in Zenas BioPharma, Inc. during the relevant time frame, you have until June 16, 2025<\/strong>\u00a0to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff.<\/p>\n

\n NO COST TO YOU: <\/strong>If you are a class member, you may be entitled to compensation without payment of any out-of-pocket costs or fees. There is no cost or obligation to participate.<\/strong><\/p>\n

\n WHY LEVI & KORSINSKY: <\/strong>Over the past 20 years, the team at Levi & Korsinsky has secured hundreds of millions of dollars for aggrieved shareholders and built a track record of winning high-stakes cases. Our firm has extensive expertise representing investors in complex securities litigation and a team of over 70 employees to serve our clients. For seven years in a row, Levi & Korsinsky has ranked in ISS Securities Class Action Services\u2019 Top 50 Report as one of the top securities litigation firms in the United States.<\/p>\n

\n CONTACT:<\/strong>
\n
Levi & Korsinsky, LLP
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
33 Whitehall Street, 17th Floor
New York, NY 10004
jlevi@levikorsinsky.com<\/a>\u00a0
Tel: (212) 363-7500
Fax: (212) 363-7171
www.zlk.com<\/a>\u00a0<\/p>\n

\"\"
\n
\n \"\"\n <\/div>\n

<\/div>\n","protected":false},"excerpt":{"rendered":"

NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. (“Zenas BioPharma, Inc.” or the “Company”) (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and\/or traceable to the registration statement and related prospectus issued in connection with Zenas BioPharma\u2019s September 2024 initial public offering. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/zenas-biopharma-inc-lawsuit-submission-form?prid=148677&wire=3 ZBIO investors may also contact Joseph E. Levi, Esq. via email … <\/p>\n

Continue reading “Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights \u2013 ZBIO”<\/span><\/a><\/p>\n","protected":false},"author":2,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[],"tags":[],"class_list":["post-851975","post","type-post","status-publish","format-standard","hentry"],"yoast_head":"\nShareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights \u2013 ZBIO - Market Newsdesk<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-zenas-biopharma-inc-should-contact-levi-korsinsky-before-june-16-2025-to-discuss-your-rights-zbio-2\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights \u2013 ZBIO - Market Newsdesk\" \/>\n<meta property=\"og:description\" content=\"NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. (“Zenas BioPharma, Inc.” or the “Company”) (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and\/or traceable to the registration statement and related prospectus issued in connection with Zenas BioPharma\u2019s September 2024 initial public offering. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/zenas-biopharma-inc-lawsuit-submission-form?prid=148677&wire=3 ZBIO investors may also contact Joseph E. Levi, Esq. via email … Continue reading "Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights \u2013 ZBIO"\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-zenas-biopharma-inc-should-contact-levi-korsinsky-before-june-16-2025-to-discuss-your-rights-zbio-2\/\" \/>\n<meta property=\"og:site_name\" content=\"Market Newsdesk\" \/>\n<meta property=\"article:published_time\" content=\"2025-05-16T17:22:49+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MjU3MyM2OTQ0Njc0IzIwMjA0MjY=\" \/>\n<meta name=\"author\" content=\"Newsdesk\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Newsdesk\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"2 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-of-zenas-biopharma-inc-should-contact-levi-korsinsky-before-june-16-2025-to-discuss-your-rights-zbio-2\\\/#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-of-zenas-biopharma-inc-should-contact-levi-korsinsky-before-june-16-2025-to-discuss-your-rights-zbio-2\\\/\"},\"author\":{\"name\":\"Newsdesk\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"headline\":\"Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights \u2013 ZBIO\",\"datePublished\":\"2025-05-16T17:22:49+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-of-zenas-biopharma-inc-should-contact-levi-korsinsky-before-june-16-2025-to-discuss-your-rights-zbio-2\\\/\"},\"wordCount\":404,\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-of-zenas-biopharma-inc-should-contact-levi-korsinsky-before-june-16-2025-to-discuss-your-rights-zbio-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1MjU3MyM2OTQ0Njc0IzIwMjA0MjY=\",\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-of-zenas-biopharma-inc-should-contact-levi-korsinsky-before-june-16-2025-to-discuss-your-rights-zbio-2\\\/\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-of-zenas-biopharma-inc-should-contact-levi-korsinsky-before-june-16-2025-to-discuss-your-rights-zbio-2\\\/\",\"name\":\"Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights \u2013 ZBIO - Market Newsdesk\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-of-zenas-biopharma-inc-should-contact-levi-korsinsky-before-june-16-2025-to-discuss-your-rights-zbio-2\\\/#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-of-zenas-biopharma-inc-should-contact-levi-korsinsky-before-june-16-2025-to-discuss-your-rights-zbio-2\\\/#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1MjU3MyM2OTQ0Njc0IzIwMjA0MjY=\",\"datePublished\":\"2025-05-16T17:22:49+00:00\",\"author\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\"},\"breadcrumb\":{\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-of-zenas-biopharma-inc-should-contact-levi-korsinsky-before-june-16-2025-to-discuss-your-rights-zbio-2\\\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-of-zenas-biopharma-inc-should-contact-levi-korsinsky-before-june-16-2025-to-discuss-your-rights-zbio-2\\\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-of-zenas-biopharma-inc-should-contact-levi-korsinsky-before-june-16-2025-to-discuss-your-rights-zbio-2\\\/#primaryimage\",\"url\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1MjU3MyM2OTQ0Njc0IzIwMjA0MjY=\",\"contentUrl\":\"https:\\\/\\\/www.globenewswire.com\\\/newsroom\\\/ti?nf=OTQ1MjU3MyM2OTQ0Njc0IzIwMjA0MjY=\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/shareholders-of-zenas-biopharma-inc-should-contact-levi-korsinsky-before-june-16-2025-to-discuss-your-rights-zbio-2\\\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights \u2013 ZBIO\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#website\",\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/\",\"name\":\"Market Newsdesk\",\"description\":\"Latest Business News in Real Time\",\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/#\\\/schema\\\/person\\\/482f27a394d4fda80ecb5499e519d979\",\"name\":\"Newsdesk\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g\",\"caption\":\"Newsdesk\"},\"url\":\"https:\\\/\\\/www.marketnewsdesk.com\\\/index.php\\\/author\\\/newsdesk\\\/\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights \u2013 ZBIO - Market Newsdesk","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-zenas-biopharma-inc-should-contact-levi-korsinsky-before-june-16-2025-to-discuss-your-rights-zbio-2\/","og_locale":"en_US","og_type":"article","og_title":"Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights \u2013 ZBIO - Market Newsdesk","og_description":"NEW YORK, May 16, 2025 (GLOBE NEWSWIRE) — Levi & Korsinsky, LLP notifies investors in Zenas BioPharma, Inc. (“Zenas BioPharma, Inc.” or the “Company”) (NASDAQ: ZBIO) of a class action securities lawsuit. CLASS DEFINITION: The lawsuit seeks to recover losses on behalf of Zenas BioPharma, Inc. investors who were adversely affected by alleged securities fraud. This lawsuit is on behalf of persons who purchased or otherwise acquired Zenas BioPharma securities pursuant and\/or traceable to the registration statement and related prospectus issued in connection with Zenas BioPharma\u2019s September 2024 initial public offering. Follow the link below to get more information and be contacted by a member of our team: https:\/\/zlk.com\/pslra-1\/zenas-biopharma-inc-lawsuit-submission-form?prid=148677&wire=3 ZBIO investors may also contact Joseph E. Levi, Esq. via email … Continue reading \"Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights \u2013 ZBIO\"","og_url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-zenas-biopharma-inc-should-contact-levi-korsinsky-before-june-16-2025-to-discuss-your-rights-zbio-2\/","og_site_name":"Market Newsdesk","article_published_time":"2025-05-16T17:22:49+00:00","og_image":[{"url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MjU3MyM2OTQ0Njc0IzIwMjA0MjY=","type":"","width":"","height":""}],"author":"Newsdesk","twitter_card":"summary_large_image","twitter_misc":{"Written by":"Newsdesk","Est. reading time":"2 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-zenas-biopharma-inc-should-contact-levi-korsinsky-before-june-16-2025-to-discuss-your-rights-zbio-2\/#article","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-zenas-biopharma-inc-should-contact-levi-korsinsky-before-june-16-2025-to-discuss-your-rights-zbio-2\/"},"author":{"name":"Newsdesk","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"headline":"Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights \u2013 ZBIO","datePublished":"2025-05-16T17:22:49+00:00","mainEntityOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-zenas-biopharma-inc-should-contact-levi-korsinsky-before-june-16-2025-to-discuss-your-rights-zbio-2\/"},"wordCount":404,"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-zenas-biopharma-inc-should-contact-levi-korsinsky-before-june-16-2025-to-discuss-your-rights-zbio-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MjU3MyM2OTQ0Njc0IzIwMjA0MjY=","inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-zenas-biopharma-inc-should-contact-levi-korsinsky-before-june-16-2025-to-discuss-your-rights-zbio-2\/","url":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-zenas-biopharma-inc-should-contact-levi-korsinsky-before-june-16-2025-to-discuss-your-rights-zbio-2\/","name":"Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights \u2013 ZBIO - Market Newsdesk","isPartOf":{"@id":"https:\/\/www.marketnewsdesk.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-zenas-biopharma-inc-should-contact-levi-korsinsky-before-june-16-2025-to-discuss-your-rights-zbio-2\/#primaryimage"},"image":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-zenas-biopharma-inc-should-contact-levi-korsinsky-before-june-16-2025-to-discuss-your-rights-zbio-2\/#primaryimage"},"thumbnailUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MjU3MyM2OTQ0Njc0IzIwMjA0MjY=","datePublished":"2025-05-16T17:22:49+00:00","author":{"@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979"},"breadcrumb":{"@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-zenas-biopharma-inc-should-contact-levi-korsinsky-before-june-16-2025-to-discuss-your-rights-zbio-2\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-zenas-biopharma-inc-should-contact-levi-korsinsky-before-june-16-2025-to-discuss-your-rights-zbio-2\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-zenas-biopharma-inc-should-contact-levi-korsinsky-before-june-16-2025-to-discuss-your-rights-zbio-2\/#primaryimage","url":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MjU3MyM2OTQ0Njc0IzIwMjA0MjY=","contentUrl":"https:\/\/www.globenewswire.com\/newsroom\/ti?nf=OTQ1MjU3MyM2OTQ0Njc0IzIwMjA0MjY="},{"@type":"BreadcrumbList","@id":"https:\/\/www.marketnewsdesk.com\/index.php\/shareholders-of-zenas-biopharma-inc-should-contact-levi-korsinsky-before-june-16-2025-to-discuss-your-rights-zbio-2\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.marketnewsdesk.com\/"},{"@type":"ListItem","position":2,"name":"Shareholders of Zenas BioPharma, Inc. Should Contact Levi & Korsinsky Before June 16, 2025 to Discuss Your Rights \u2013 ZBIO"}]},{"@type":"WebSite","@id":"https:\/\/www.marketnewsdesk.com\/#website","url":"https:\/\/www.marketnewsdesk.com\/","name":"Market Newsdesk","description":"Latest Business News in Real Time","potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.marketnewsdesk.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Person","@id":"https:\/\/www.marketnewsdesk.com\/#\/schema\/person\/482f27a394d4fda80ecb5499e519d979","name":"Newsdesk","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/a0d0bd5b0f0ca12a265a459b13169dac35f33776d8501eda5e68844a366f2f46?s=96&d=mm&r=g","caption":"Newsdesk"},"url":"https:\/\/www.marketnewsdesk.com\/index.php\/author\/newsdesk\/"}]}},"_links":{"self":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/851975","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/users\/2"}],"replies":[{"embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/comments?post=851975"}],"version-history":[{"count":0,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/posts\/851975\/revisions"}],"wp:attachment":[{"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/media?parent=851975"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/categories?post=851975"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.marketnewsdesk.com\/index.php\/wp-json\/wp\/v2\/tags?post=851975"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}